abrdn plc Sells 13,484 Shares of Hologic, Inc. (NASDAQ:HOLX)

abrdn plc lowered its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 3.5% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 370,538 shares of the medical equipment provider's stock after selling 13,484 shares during the period. abrdn plc owned 0.16% of Hologic worth $26,653,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Benson Investment Management Company Inc. acquired a new stake in shares of Hologic in the fourth quarter valued at approximately $4,832,000. Clean Yield Group lifted its holdings in Hologic by 18.9% during the 4th quarter. Clean Yield Group now owns 45,646 shares of the medical equipment provider's stock valued at $3,291,000 after purchasing an additional 7,266 shares during the last quarter. GAMMA Investing LLC boosted its position in Hologic by 17.9% during the third quarter. GAMMA Investing LLC now owns 3,832 shares of the medical equipment provider's stock worth $312,000 after purchasing an additional 582 shares during the period. Janus Henderson Group PLC increased its holdings in shares of Hologic by 2.9% in the third quarter. Janus Henderson Group PLC now owns 28,776 shares of the medical equipment provider's stock valued at $2,344,000 after purchasing an additional 800 shares during the last quarter. Finally, Versor Investments LP acquired a new position in shares of Hologic in the third quarter valued at $1,677,000. Institutional investors own 94.73% of the company's stock.

Hologic Price Performance

Hologic stock traded down $0.87 during midday trading on Friday, reaching $64.58. The company's stock had a trading volume of 3,846,270 shares, compared to its average volume of 2,558,621. The company has a current ratio of 3.49, a quick ratio of 3.03 and a debt-to-equity ratio of 0.52. The stock has a market cap of $14.58 billion, a PE ratio of 20.37, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. Hologic, Inc. has a 52 week low of $63.88 and a 52 week high of $84.67. The business has a 50-day moving average price of $72.33 and a 200-day moving average price of $77.76.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, sell-side analysts predict that Hologic, Inc. will post 4.27 EPS for the current year.

Insider Activity at Hologic

In related news, COO Essex D. Mitchell sold 24,856 shares of the firm's stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the transaction, the chief operating officer now owns 27,957 shares in the company, valued at $2,134,237.38. This trade represents a 47.06 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.88% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Wolfe Research began coverage on shares of Hologic in a report on Friday, December 13th. They set a "peer perform" rating for the company. William Blair reiterated an "outperform" rating on shares of Hologic in a research note on Thursday. StockNews.com raised shares of Hologic from a "hold" rating to a "buy" rating in a report on Thursday, November 14th. Morgan Stanley cut their price target on Hologic from $84.00 to $82.00 and set an "equal weight" rating for the company in a research note on Monday, January 13th. Finally, JPMorgan Chase & Co. raised their price objective on Hologic from $92.00 to $94.00 and gave the stock an "overweight" rating in a research note on Tuesday, November 5th. Ten research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $85.77.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.